Back to Screener

Healthcare

Corbus Pharmaceuticals Holdings Inc(CRBP)

Live Price

Offline

$8.74

+5.94% today

1Y Change

+22.61%

Window

Jun 30, 2025 โ†’ Jun 23, 2026

Market Cap
$130.00M
Revenue Growth
0.0%
EPS Growth
-60.3%
Dividend Yield
0.0%

Coverage: 246 bars ยท Jun 30, 2025 โ†’ Jun 23, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Corbus Pharmaceuticals Holdings Inc (CRBP) is a Healthcare stock with a market cap of $130.00M and listed on NASDAQ. The stock last traded around $8.74 and up 22.6% across the available one-year price window (Jun 30, 2025 โ†’ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -60.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -60.3%, free cash flow -54.3% with operating margin 0.0% and ROIC -57.2%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CRBP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

CRBP vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

Relative Read

Mixed setup vs SPY

CRBP is 3.88 pts ahead over the shared 1Y window.

CRBP had 52.75 pts deeper max drawdown than SPY.

CRBP beat SPY in 2 of 2 calendar years shown and trailed in 0.

CRBP

+22.61%

Normalized return

SPY

+18.73%

S&P 500

Excess Return

+3.88 pts

Relative to SPY

CRBP Max Drawdown

-61.88%

Trailing 1Y

SPY Max Drawdown

-9.13%

Trailing 1Y

CRBPSPY

Calendar-Year Returns

Uses the longest available daily history for CRBP and SPY.

YearCRBPSPYExcessLeader
2026+7.50%+6.71%+0.79 ptsCRBP
2025+16.09%+11.19%+4.89 ptsCRBP

Unable to load analyst forecasts.

Timed out loading forecasts for CRBP

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.